Citius Oncology FY26 Q3 net loss widens to $8.9 million; revenue rises to $1.5 million

Reuters2026/08/14 20:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Citius Oncology posted revenue of USD 1.49 million for fiscal Q3 ended June 30, 2026, versus no revenue a year earlier.
Net loss widened to USD 8.92 million, or USD 0.08 per share, from USD 5.37 million, or USD 0.08 per share.
Cash and cash equivalents rose to USD 16.56 million as of June 30, 2026; nine-month revenue reached USD 7.11 million.
Institutional vial orders rose 31% sequentially to 926; July orders climbed to 383, the largest month to date.
Leonard Mazur said a 29-person commercial team now provides nationwide coverage, targeting formulary inclusion at 100 priority institutions by year-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608141630PR_NEWS_USPR_____NY26850) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Citius Oncology FY26 Q3 net loss widens to $8.9 million; revenue rises to $1.5 million

You may also like

Crypto prices